Accedi
Accedi
Oppure accedi con
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registrati
Oppure accedi con
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Home
  2. Azioni
  3. Svezia
  4. Nasdaq Stockholm
  5. Intervacc AB (publ)
  6. Notizie
  7. Altre lingue
    IVACC   SE0009607252

INTERVACC AB (PUBL)

(IVACC)
  Rapporto
Tempo differito Nasdaq Stockholm  -  17:29:55 31/01/2023
22.22 SEK   -0.89%
2022Intervacc e l'Università Svedese di Scienze Agrarie, SLU, estendono il contratto pluriennale per lo sviluppo di vaccini innovativi per la salute degli animali.
CI
2022Intervacc AB (Publ) annuncia che Strangvac, un vaccino contro lo strangolamento degli equini, è stato rilasciato per la vendita in Italia
CI
2022Il vaccino contro lo strangolamento degli equini di Intervacc inizia ad essere venduto in Polonia
MT
RiassuntoQuotazioniGraficiNotizieRatingCalendarioSocietąFinanzaConsensusRevisioniDerivatiFondi 
RiassuntoTutte le notizieAltre lingueComunicati stampaPubblicazioni ufficialiNotizie del settore
Notizie in altre lingue su INTERVACC AB (PUBL)
24/01Intervacc's Chief Scientific Officer Dr Andrew Waller presents at the FEEVA European Ho..
23/01Intervacc's Chief Scientific Officer Dr Andrew Waller presents at the Veterinary Sport ..
2022Intervacc and the Swedish University of Agricultural Sciences, SLU, extends a multi-yea..
2022Intervacc and the Swedish University of Agricultural Sciences, SLU, Extends Multi-Year ..
2022Strangvac, a vaccine against equine strangles released for sales in Italy
2022Intervacc AB Announces Strangvac, A Vaccine Against Equine Strangles Released for Sales..
2022Intervacc's Equine Strangles Vaccine Starts Selling in Poland
2022Strangvac, a vaccine against equine strangles, is now available for sale in Poland
2022Intervacc's Chief Scientific Officer Dr Andrew Waller participate at the Dutch Equine C..
2022Intervacc's Chief Scientific Officer Dr Andrew Waller will speak about the prevention o..
2022Intervacc to Launch Horse Infection Vaccine in Ireland
2022Strangvac sales to start in Ireland
2022Nomination Committee appointed in respect of AGM 2023 in Intervacc
2022Intervacc AB Reports Earnings Results for the Third Quarter and Nine Months Ended Septe..
2022Intervacc Releases First Batch of Horse Vaccine in New EU Markets
2022Strangvac, a vaccine against equine strangles released for sales in Germany, France, Au..
2022Intervacc AB Announces First Batch of Strangvac for Sale in Germany, France, Austria, B..
2022Interim report January - June 2022
2022Intervacc AB Reports Earnings Results for the Second Quarter and Six Months Ended June ..
2022Intervacc Launches Horse Vaccine Strangvac in Britain
2022Strangvac, a vaccine against equine strangles, is now available for sale in the UK
2022Intervacc AB Announces That Strangvac Is Now Available for Sale in the Uk
2022The CEO and a number of key personnel acquires shares through the exercise of warrants ..
2022Intervacc receives order for Strangvac, a vaccine against the equine disease strangles,..
2022Intervacc AB Receives Order for Strangvac, from the Dechra Pharmaceuticals plc Group fo..
2022Strangvac, a vaccine against equine strangles released for sales in the UK
2022Report from Annual General Meeting in Intervacc
2022Intervacc AB Elects Michela De Carli as Board Member At the Annual General Meeting Held..
2022Strangvac, a vaccine against equine strangles, available for sale in Denmark
2022Intervacc Announces Strangvac, A Vaccine Against Equine Strangles, Available for Sale i..
2022Intervacc AB Reports Earnings Results for the First Quarter Ended March 31, 2022
2022Intervacc progresses vaccine to prevent mastitis in dairy cows caused by Staphylococcus..
2022Intervacc AB Announces Initiation of a Proof-Of-Concept Study to Measure the Effectiven..
2022Notice of annual general meeting in intervacc ab (publ)
2022The Norwegian Food Safety Authority change their regulations to allow vaccination of ho..
2022Positive results in proof-of-concept study to develop a vaccine against Streptococcus s..
2022Ntervacc AB Announces Positive Results from A Proof-Of-Concept Study to Develop A Vacci..
2022Intervacc publishes the 2021 Annual Report
2022Strangvac, a vaccine against equine Strangles, released for sale in Sweden
2022Intervacc Announces Release of First Batch of Strangvac, a Vaccine against Equine Stran..
2022Intervacc Up 10% After European Medicines Agency Extends Shelf Life For Vaccine's Antig..
2022The European Medicines Agency extends the shelf life of the antigens used in Strangvac ..
2022The European Medicines Agency Extends the Shelf Life of the Antigens Used in Strangvac ..
2022Intervacc AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2021
2022Intervacc AB Reports Earnings Results for the Full Year Ended December 31, 2021
2022Sweden's Intervacc Seeks Permit to Sell Strangles Vaccine For Horses in US; Shares Up 5..
2022Intervacc applies for a Permit for Sale and Distribution of Strangvac in the U.S.
2022Intervacc Applies for A Permit for Sale and Distribution of Strangvac in the U.S
2022Intervacc Seeks Supplementary Protection Certificates For Horse Vaccine Patent In Europ..
2022Intervacc has applied for supplementary protection certificates for Strangvac in key Eu..
2022Intervacc Applies for Supplementary Protection Certificates for Strangvac in Key Europe..
2022Intervacc's Shares Jump 11% On Favorable Results Of Horse Vaccine Trial
2022New study confirms that Strangvac is likely to be effective against all known strains o..
2021Intervacc: Clarification regarding Intervacc's vaccine Strangvac
2021Clarification regarding Intervacc's vaccine Strangvac
2021Intervacc AB Announces Clarification Regarding Intervacc's Vaccine Strangvac
2021Intervacc Urges Horse Owners to Conduct Infection Control After Strangles Vaccination
2021Intervacc comments on the trading halt of the company's share on Nasdaq First North
2021Sales launch of Intervacc vaccine against equine Strangles during Q1 2022
2021Nomination Committee appointed in respect of AGM 2022 in Intervacc
2021Intervacc AB Appoints Nomination Committee
2021Interim report January - September 2021
2021Intervacc AB Reports Earnings Results for the Third Quarter and Nine Months Ended Septe..
2021Intervacc Gets US Patent For Streptococcus Suis Vaccine In Pigs
2021U.S. patent approval for Intervacc's vaccine against infections caused by Streptococcus..
2021U.S. patent approval for Intervacc's vaccine against infections caused by Streptococcus..
2021Intervacc AB Announces U.S. Patent Approval for Intervacc's Vaccine Against Infections ..
2021Intervacc : Horse Vaccine Receives Approval From UK Regulatory Body
2021Intervacc: Strangvac, a vaccine against equine strangles, has been granted marketing auth..
2021Intervacc: Interim report January – June 2021
2021Intervacc: Interim report January - June 2021
2021Intervacc AB Announces Earnings Results for the Second Quarter and Six Months Ended Jun..
2021Intervacc: brings forward the report for the first half of 2021 to August 31, 2021
2021Intervacc : Horse Vaccine Wins Norwegian Approval
2021Intervacc: Strangvac, a vaccine against equine strangles, has been granted marketing auth..
2021Intervacc AB Announces Norwegian Medicines Agency Grants Marketing Authorisation for St..
2021Intervacc: Strangvac, a vaccine against equine strangles, has been granted marketing auth..
2021European Commission Grants a Marketing Authorisation for Strangvac® Within the European..
2021Intervacc : Application for Horse Vaccine Gets Positive Outcome From UK Veteri..
2021Intervacc: receives confirmation of a positive outcome for Strangvac, a vaccine against e..
2021Intervacc Receives Confirmation of a Positive Outcome for Strangvac, a Vaccine against ..
2021Intervacc: receives positive CVMP opinion for Strangvac, a vaccine against equine strangl..
2021Intervacc AB Receives Positive CVMP Opinion for Strangvac, A Vaccine Against Equine Str..
2021Intervacc: Report from Annual General Meeting in Intervacc
2021Intervacc AB Declines Re-Election of Newton Aquiar as Board Member
2021Intervacc: CEO presentation AGM
2021Intervacc: and the Karolinska Institutet sign a multi-year contract for the development o..
2021Intervacc and the Karolinska Institutet Sign A Multi-Year Contract for the Development ..
2021Intervacc: Interim report January – March 2021
2021Intervacc AB Announces Consolidated and Parent Earnings Results for the First Quarter E..
2021Intervacc: Notice of annual general meeting in Intervacc AB (publ)
2021Dechra Pharmaceuticals : To Commercialize Intervacc's Strangvac i..
2021Intervacc Ab: and Dechra Pharmaceuticals PLC enter into an Agreement to Commercialize Str..
2021Intervacc AB and Dechra Pharmaceuticals plc Enter into an Agreement to Commercialize St..
2021Intervacc: publishes the 2020 Annual Report
2021Intervacc: DNA investigation highlights the 'unbridled globetrotting' of the Strangles pa..
2021Intervacc Reports Earnings Results for the Fourth Quarter and Full Year Ended December ..
2021Intervacc: Announces Submission of Responses to EMA Day 120 Questions
2020Intervacc: appoints Emma Hartman as Global Product Manager for Strangvac
2020Intervacc AB Appoints Emma Hartman as Global Product Manager for Strangvac
Prossimo evento su INTERVACC AB (PUBL)